StockData

Evaxion A/S vs TScan Therapeutics

EVAX and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EVAX and TCRX compare

Evaxion A/S grew revenue faster over the last twelve months (125% versus 2.2% for TScan Therapeutics).

Evaxion A/S keeps more of each dollar of sales as profit, with a net margin of −102% compared with −1655% at TScan Therapeutics.

TScan Therapeutics scores higher on the StockData Score (4 against 2 for Evaxion A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEVAXTCRX
Size and price
Market cap–$9.8M
Share price$2.77$0.145
Change, 1 year−51.5%−87.2%
Change, 5 years−98.9%−98.3%
Beta (5Y)1.292.20
Employees45142
StockData Score
Total score24 (better)
Valuation score03 (better)
Growth score1 (better)0
Performance score00
Health score11
Dividend score00
Valuation
P/S–1.4×
P/B–0.1×
FCF yield–−1204%
Fair value–$1.36
Margin of safety–89.3%
Growth
Revenue growth (TTM)125% (better)2.2%
Revenue growth, 5Y average–56.9%
Profitability
Operating margin−123% (better)−1695%
Net margin−102% (better)−1655%
FCF margin−88.2% (better)−1666%
Return on equity–−95.8%
Financial health
Debt / equity–0.47
Interest coverage−2.3× (better)−43.2×
Current ratio5.06 (better)3.37
Altman Z-score–−6.31
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.38%53.5%
Held by insiders3.5%32.8%
Insider net buying, 12 months–$146K
Short interest, % of float–4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.